We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - [Midatech Pharma plc]

27 May 2020 07:00

RNS Number : 9950N
Lind Partners, LLC (The)
26 May 2020
 

FORM 8.3

 

PUBLIC DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

The Lind Partners, LLC

 

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Midatech Pharma Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

22 May 2020, in addition, The Lind Partners has dealt further in previous days during the offer period as shown in the bottom of the form.

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

US ADRs: US59564R3021

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

80,040 ADRs

(equivalent to 400,200 shares)

1.02

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

80,040 ADRs

(equivalent to 400,200 shares)

1.02

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Warrants to purchase ADRs

Details, including nature of the rights concerned and relevant percentages:

193,940 warrants with a strike price of USD 2.05 issued without payment alongside placement of an equivalent number of ADRs on 18 May 2020

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

US ADRs (US59564R3021)

Sale

 

15,000

USD 1.437

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES/NO NO

 

 

Date of disclosure:

26 May 2020

Contact name:

Samantha Chun

Telephone number*:

+1(646) 701-7424

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

Class of relevant security

Date

Purchase/sale

 

Number of securities

Price per unit

US ADRs (US59564R3021)

18 May 2020

Subscription (issuance of ADRs pursuant to a private placement)

 

193,940

 

USD 1.65

 

US ADRs (US59564R3021)

18 May 2020

Sale

51,400

USD 1.614

US ADRs (US59564R3021)

19 May 2020

Sale

17,500

USD 1.578

US ADRs (US59564R3021)

20 May 2020

Sale

15,000

USD 1.509

US ADRs (US59564R3021)

21 May 2020

Sale

15,000

USD 1.485

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETKKABNOBKDDPB
Date   Source Headline
20th Dec 20177:00 amRNSMidatech initiates Gelclair Phase IV trial
22nd Nov 20177:00 amRNSMidatech receives manufacturing certification
7th Nov 20179:35 amRNSIssue of Equity for Midatech Share Incentive Plan
19th Oct 201710:52 amRNSHolding(s) in Company
19th Oct 20179:44 amRNSHoldings in Company
16th Oct 201712:44 pmRNSResult of General Meeting
28th Sep 20172:35 pmRNSResult of Placing to raise £6m & PDMR Shareholding
28th Sep 20177:01 amRNSInterim Results 2017
28th Sep 20177:00 amRNSProposed Placing and Open Offer
21st Sep 20179:00 amRNSHolding(s) in Company
7th Sep 20177:00 amRNSNotice of interim results
4th Sep 20177:00 amRNSMidatech submits MTD201 CTA filing
25th Aug 20171:59 pmRNSHolding(s) in Company
26th Jul 20177:00 amRNSCompletion of pre-clinical liver cancer programme
18th Jul 20177:00 amRNSTrading Update and Notice of Results
13th Jun 20177:00 amRNSSite visit for investors and analysts
7th Jun 20177:00 amRNSMidatech signs global agreement for panobinostat
22nd May 20177:00 amRNSProgress update on brain cancer therapies
19th May 20173:12 pmRNSIssue of Equity for Midatech Share Incentive Plan
3rd May 20172:30 pmRNSResult of AGM
4th Apr 20177:02 amRNSFinancial results for year ended 31 December 2016
14th Mar 20177:00 amRNSNotice of Results
10th Mar 20177:00 amRNSMidatech Announces Initial Scale-Up of Facility
27th Feb 20177:00 amRNSMidatech enters into Loan Agreement with SVB
20th Jan 201711:05 amRNSSecond Price Monitoring Extn
20th Jan 201711:00 amRNSPrice Monitoring Extension
20th Jan 20177:00 amRNSTrading Update
20th Dec 201612:56 pmRNSDirector/PDMR Shareholding
15th Dec 20164:31 pmRNSHolding(s) in Company
22nd Nov 20167:00 amRNSMidatech receives upfront on Emergex vaccine deal
15th Nov 20167:00 amRNSMidatech selects MTR104 for liver cancer treatment
2nd Nov 201612:57 pmRNSHolding(s) in Company
2nd Nov 20169:51 amRNSHolding(s) in Company
28th Oct 201611:12 amRNSResult of GM, Open Offer & Issue of Equity
11th Oct 20162:59 pmRNSResults of Placing to raise £16.0 million
11th Oct 201611:18 amRNSProposed Placing and Open Offer
30th Sep 20167:00 amRNSFirst in Human Immunotherapy Study Start
21st Sep 20167:00 amRNSMidatech Pharma US Partnership with R-Pharm US
2nd Sep 20167:00 amRNSInterim Results
10th Aug 20167:00 amRNSTrading Update and Notice of Results
7th Jul 20168:15 amRNSMidatech receives grant funding
30th Jun 20161:11 pmRNSAnnual Report Posting
27th Jun 20167:00 amRNSIssue of Equity and Director's Dealings
18th May 20167:00 amRNSMidatech Pharma announces clinical pipeline update
11th May 20165:28 pmRNSResult of AGM
11th May 20167:00 amRNSAGM Statement and Update on Trading
26th Apr 20167:00 amRNSMidatech announces positive Q-Octreotide data
21st Apr 20167:00 amRNSPositive data for OpsiSporin Uveitis programme
13th Apr 20167:00 amRNSFinancial results for the year ended 31 Dec 2015
11th Apr 20167:00 amRNSCommercial Launch of Zuplenz® (Ondansetron) in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.